

N19 - Dialysis Adequacy and Quality Review

When: The monthly adequacy result, recurrent shortened sessions, or symptoms despite an acceptable Kt/V.

Do this

- Confirm sampling technique and timing for pre/post urea. Compare delivered treatment time with the prescription and identify missed or shortened sessions.
- Review blood-flow delivery, repeated alarms, interruptions, access findings, and recent access procedures when Kt/V falls.
- For conventional three-times-weekly HD, distinguish the KDOQI target spKt/V of 1.4 from the minimum delivered value of 1.2 [1]. Report results below the prescribed goal.
- Review symptoms, volume tolerance, recovery time, intake/weight change, function, and the patient's own priorities alongside adequacy.

Call / escalate

- An unexplained fall or result below target, recurrent inability to complete treatment, or an abnormal access examination: arrange prompt team review.
- Breathlessness, chest pain, confusion, arrhythmia symptoms, or acute access failure: use the urgent clinical pathway; do not wait for monthly rounds.

Don't

- Do not shorten prescribed treatment because Kt/V is above a threshold.
- Do not apply a per-session spKt/V target to a different dialysis schedule without the nephrologist's prescription, or change blood flow, time, or dialyzer independently.

Evidence numbers refer to the sources on the reverse.

N19 - Dialysis Adequacy and Quality Review

Why

- Kt/V describes urea clearance. It does not measure every treatment goal or capture how a patient feels [1,2].
- The HEMO trial did not find an overall survival benefit from increasing the small-solute dose above the standard-dose arm. Meeting a minimum is necessary; chasing a higher number is not a complete quality plan [2].
- A meaningful review connects the result to delivered treatment, access performance, safety, nutrition, symptoms, and patient goals.

Bring this to the review

Prescription and actual minutes; sampling method; Kt/V trend; missed sessions; blood-flow/pressure alarms; access findings; symptoms and recovery time; barriers and a specific follow-up plan.

Sources - click to open

1. [KDOQI Hemodialysis Adequacy: 2015 Update. PMID: 26498416](#)
2. [HEMO trial. N Engl J Med. 2002. PMID: 12490682](#)

Full reviews and navigation

[Adequacy, Nutrition, Depression, and Cognition - and What Quality Metrics Miss](#)

[Ultrafiltration rate and treatment time](#)

[Complete screening and health maintenance white paper](#)

[All nursing cards](#) | [HD section home](#) | [Main homepage](#)

Adapted from the linked Clinical Mastery reviews. Updated September 27, 2026. Andrew Bland, MD, FACP, FAAP - Urine Nephrology Now.